Zolbetuximab with chemotherapy for advanced stomach cancer
Part of Cancer, Digestive system clinical trials.
This study looks at how well zolbetuximab works when combined with chemotherapy in people with advanced stomach or gastroesophageal junction cancer. It aims to help doctors understand the best ways to use this treatment in everyday practice.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery.
- You are at least 18 years old.
- Your cancer tests negative for HER2 (a protein that can make cancer grow).
- Your cancer shows a specific marker called CLDN18.2, meaning at least 75% of your tumor cells have this protein.
- You have not had another cancer (other than non-melanoma skin cancer) in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called zolbetuximab added to standard chemotherapy for people with advanced stomach or gastroesophageal junction cancer. It may help slow the cancer's growth.
This trial tests a new combination of drugs (zolbetuximab, pembrolizumab, and chemotherapy) for people with advanced stomach or gastroesophageal junction cancer. It may be an option if your tumor has certain proteins (CLDN18.2 and PD-L1) and you haven't had chemotherapy for advanced disease.
This early access program offers the investigational drug zolbetuximab for people with advanced stomach cancer that has a specific protein marker. The study aims to make this targeted treatment available before it is fully approved, potentially helping those who have limited options.
This trial tests a new drug called zolbetuximab combined with chemotherapy (docetaxel, oxaliplatin, S-1) before surgery for people with locally advanced stomach cancer that has a specific protein (CLDN18.2). The goal is to see if this combination shrinks tumors enough to improve surgery outcomes.
This trial tests a combination of three drugs (zolbetuximab, paclitaxel, and ramucirumab) for people with advanced stomach or esophagus cancer that has a specific protein called CLDN18.2. It may be an option if you've already had one standard treatment.
This trial is looking at a drug called zolbetuximab, given with chemotherapy, for people with a certain type of stomach or gastroesophageal junction cancer that has spread and has high levels of a protein called claudin 18.2. The goal is to see how well it works in real-world settings.
Hear when a new Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.